Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)

IMRT With Concurrent Chemotherapy and Cetuximab Against Locoregionally Advanced NPC: a Phase 1 Study

The investigators will add weekly cetuximab (c225) to the standard care of chemoradiation against locoregionally advanced Nasopharyngeal Carcinoma (NPC), and evaluate the toxicity and efficacy of this new regimen.

Inclusion Criteria:

• Pathologically confirmed untreated NPC patients
• locoregionally advanced (T3-4 or N2-3 M0)
• 18-65 years
• with MRI examinations
• ECOG ≤ 2
• With written consent

Exclusion Criteria:

• Without a second cancer
• Pregnancy
• With other severe diseases (blood,liver ,kidney or heart diseases)
• Could not be staged properly
• Without written consent